Baidu
map

血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018)

2018-09-17 中国心血管相关专家小组(统称) 中国介入心脏病学杂志.2018,26(8):421-424.

为整体提升临床医师对RAASi 在冠心病患者中的规范化使用,提高临床医师对ARB 的认识,针对ARB 用于治疗冠心病患者的临床建议具有较大的实践指导意义。因此,撰写《血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议》非常必要。

中文标题:

血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018)

发布日期:

2018-09-17

简要介绍:

为整体提升临床医师对RAASi 在冠心病患者中的规范化使用,提高临床医师对ARB 的认识,针对ARB 用于治疗冠心病患者的临床建议具有较大的实践指导意义。因此,撰写《血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议》非常必要。 

拓展指南:冠心病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018))] GetToolGuiderByIdResponse(projectId=1, id=6ab761c0016a3202, title=血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018), enTitle=, guiderFrom=中国介入心脏病学杂志.2018,26(8):421-424., authorId=null, author=, summary=为整体提升临床医师对RAASi 在冠心病患者中的规范化使用,提高临床医师对ARB 的认识,针对ARB 用于治疗冠心病患者的临床建议具有较大的实践指导意义。因此,撰写《血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议》非常必要。 , cover=, journalId=null, articlesId=null, associationId=306, associationName=中国心血管相关专家小组(统称), associationIntro=本制定者非特指某个专家小组,为统称。, copyright=0, guiderPublishedTime=Mon Sep 17 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>为整体提升临床医师对RAASi 在冠心病患者中的规范化使用,提高临床医师对ARB 的认识,针对ARB 用于治疗冠心病患者的临床建议具有较大的实践指导意义。因此,撰写《血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议》非常必要。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>冠心病</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=965761c0015925ab" title="脑卒中合并稳定性冠心病运动康复专家共识" target=_blank>脑卒中合并稳定性冠心病运动康复专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=7844e1c0015e81fa" title="冠心病心绞痛介入前后中医诊疗指南" target=_blank>冠心病心绞痛介入前后中医诊疗指南</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=749651c001569069" title="冠心病稳定型心绞痛中医诊疗专家共识" target=_blank>冠心病稳定型心绞痛中医诊疗专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=69d3d1c0015222d3" title="稳定性冠心病无创影像检查路径的专家共识" target=_blank>稳定性冠心病无创影像检查路径的专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=d5a551c001a944d6" title="75岁及以上稳定性冠心病患者运动康复中国家共识" target=_blank>75岁及以上稳定性冠心病患者运动康复中国家共识</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E5%86%A0%E5%BF%83%E7%97%85" target=_blank>有关冠心病更多指南</a></ul>, tagList=[TagDto(tagId=24514, tagName=血管紧张素Ⅱ受体拮抗剂), TagDto(tagId=703, tagName=冠心病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8520, appHits=572, showAppHits=2, pcHits=6290, showPcHits=2150, likes=149, shares=17, comments=4, approvalStatus=1, publishedTime=Sun Sep 23 20:38:49 CST 2018, publishedTimeString=2018-09-17, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Sep 23 20:38:49 CST 2018, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 03:36:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018))])
血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018)
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=974961, encodeId=a62a9e4961ab, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:00:38 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912606, encodeId=40dc912606fa, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Thu Dec 31 16:07:01 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346372, encodeId=0fad3463e20e, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Sep 24 07:35:08 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2021-06-19 ms7000001124466419

    关注

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=974961, encodeId=a62a9e4961ab, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:00:38 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912606, encodeId=40dc912606fa, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Thu Dec 31 16:07:01 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346372, encodeId=0fad3463e20e, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Sep 24 07:35:08 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2020-12-31 1e1366a1m07(暂无匿称)

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=974961, encodeId=a62a9e4961ab, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:00:38 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912606, encodeId=40dc912606fa, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Thu Dec 31 16:07:01 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346372, encodeId=0fad3463e20e, content=谢谢分享,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Sep 24 07:35:08 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-24 明月清辉

    谢谢分享,学习了

    0

Baidu
map
Baidu
map
Baidu
map